At the time of writing, Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $15.47, down -0.39%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AUPH shares have gain 3.76% over the last week, with a monthly amount glided 3.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on December 03, 2025, when Leerink Partners downgraded its rating to a Market Perform but kept the price target unchanged to $16 for it. Previously, Jefferies upgraded its rating to Buy on November 07, 2025, and kept the price target unchanged to $21. On November 05, 2025, downgrade downgraded it’s rating to Sector Perform but maintained its price target of $15 on the stock. Oppenheimer downgraded its rating to a Perform. In a note dated December 10, 2021, Oppenheimer upgraded an Outperform rating on this stock and revised its target price from $33 to $31.
For the past year, the stock price of Aurinia Pharmaceuticals Inc fluctuated between $6.55 and $16.48. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $15.47 at the most recent close of the market. An investor can expect a potential return of 0.19% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
According to Aurinia Pharmaceuticals Inc [NASDAQ:AUPH], the company’s sales were 265.81M for trailing twelve months, which represents an 8.41% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.3%, and Net Profit Margin reading is 0.29%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.22 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.34 points at the first support level, and at 15.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.70, and for the 2nd resistance point, it is at 15.93.
Ratios To Look Out For
It is important to note that Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] has a current ratio of 5.76. As well, the Quick Ratio is 5.17, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 7.67, the price to book ratio is 5.58 and price to earnings (TTM) ratio is 27.57.
Transactions by insiders
Recent insider trading involved TANG KEVIN, Director, that happened on Aug 01 ’25 when 1.0 million shares were purchased. Director, TANG KEVIN completed a deal on Aug 05 ’25 to buy 0.2 million shares. Meanwhile, Director TANG KEVIN bought 100000.0 shares on Aug 04 ’25.
